Trypanosoma cruzi sterol 14α-demethylase (TcCYP51) (TcCYP51)

Trypanosoma cruzi sterol 14α-demethylase (TcCYP51) is a member of the cytochrome P450 superfamily and a validated therapeutic target for Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (Lepesheva et al., 2011, PMID: 21214306). The enzyme plays a critical role in the sterol biosynthesis pathway, specifically catalyzing the oxidative removal of the 14α-methyl group from precursors such as lanosterol or eburicol to produce ergosterol (UniProt, Q4D950). Ergosterol is an essential component of the parasite's cell membrane, required for maintaining membrane fluidity and the function of membrane-associated proteins, whereas humans utilize cholesterol for these purposes (Buckner et al., 2012, PMID: 22547548). Inhibition of TcCYP51 by drugs such as azole antifungals leads to the depletion of ergosterol and the accumulation of toxic 14α-methylated sterol intermediates, resulting in the disruption of membrane structure and parasite death (Urbina, 2009, PMID: 19747315). Despite its high potency in vitro, clinical trials with TcCYP51 inhibitors like posaconazole and ravuconazole (E1224) have shown significant rates of treatment failure in chronic Chagas disease patients, suggesting that while the enzyme is essential, its inhibition alone may not be sufficient for a parasitological cure in all disease stages (Molina et al., 2014, PMID: 24849082).

Other names

Lanosterol 14-alpha-demethylaseCytochrome P450 51CYP51Obtusifoliol 14-demethylaseSterol 14-alpha-demethylase

Inhibition of the enzyme prevents the conversion of lanosterol or eburicol to ergosterol, leading to the accumulation of toxic 14α-methylated sterols and depletion of essential membrane ergosterol, resulting in parasite growth arrest and death.